INTRODUCTION
Although current treatment in Multiple Myeloma (MM) induces responses in >90% of patients, 1 it remains incurable for most of them. The pattern of relapse is quite heterogeneous, including frequent biochemical relapses in the absence of clinical symptoms. Although these patients can remain free of therapy for a certain period of time, they are at high at risk of symptomatic progression and therapy requirement. The current recommendation of the International Myeloma Working Group (IMWG) for patients in biological relapse is not to treat until they develop clinical symptoms, 2 except in those cases with the so-called "significant paraprotein relapse" (SPR) in whom the relapse represents a rate of rise or absolute level M protein increase at which the risk is considered very high and myeloma therapy is recommended to be restarted without any delay. 3 Intravenous Bisphosphonates (BP) are indicated in patients with MM, with or without detectable osteolytic bone lesions on conventional radiography, who are receiving antimyeloma therapy as well as patients with osteoporosis or osteopenia resulting from myeloma. 4 Although the main reason for this indication is because they prevent skeletal related events (SRE), there is also controversial data suggesting an anti-myeloma effect for Zoledronic Acid (ZOL). This hypothetical antitumor effect is based on pre-clinical studies, [5] [6] [7] reproduced in small series of patients, 8 and subanalysis of clinical trials, 9, 10 particularly, the large MRC trial, 9 conducted in newly diagnosed patients treated with either chemotherapy (CVAB) or thalidomide based therapy (CTD), that were assigned to receive either ZOL or clodronate (CLO). The ZOL group showed a significantly longer progression-free survival and overall survival compared with CLO. However, this study included several randomizations, such as thalidomide maintenance, and it is not easy to dissect the real anti-tumor versus other beneficial anti-myeloma effects of ZOL treatment. Moreover, in patients with smoldering MM, treatment with bisphosphonates did not delay transformation into symptomatic disease but it is associated with a reduction in the SRE onset. [11] [12] [13] [14] [15] [16] Accordingly, the real anti-tumor effect of bisphosphonates remains to be elucidated. Patients at biochemical relapse, in whom the standard of care is to delay treatment until symptoms emerge, represent an ideal group to investigate the anti-myeloma effect of ZOL.
The AZABACHE trial was conducted by the Spanish Myeloma Group (GEM/PETHEMA) in order to evaluate if the use of ZOL delays the time to next therapy (TNT) in patients with MM in biochemical relapse in comparison with observation.
METHODS

Trial design
In 2010, GEM/PETHEMA activated the "Analysis of Zoledronic Acid therapy in MM in
BioCHEmical relapses" trial (known from now as AZABACHE, NCT01087008). This randomized, prospective, open label phase IV trial included MM patients in asymptomatic biochemical relapse after a prior response to standard therapy. Patients were randomly distributed into two groups: 1) experimental, in which patients received Zoledronic Acid (ZOL), or 2) control (abstention), where patients did not received any treatment (No ZOL). In the experimental arm patients received ZOL, 4 mg in a 15 minutes' intravenous infusion every 4 weeks, for a total of 12 doses, plus standard supportive care (experimental group); in the control group only supportive care was permitted. The trial and all procedures were in accordance with the Helsinki Declaration and they were reviewed and approved by the Spanish National Agency and the Ethics Committee of all centers involved.
Inclusion and exclusion criteria
All patients had to fit the following inclusion criteria: 1) 18 years and older; 2) confirmed biochemical relapse after an initial response, without symptoms derived from the disease and 3)
Signed informed consent. Relapse was defined according to the IMWG criteria defined in 2006. 2 Patients treated with any symptom of myeloma Related Organ or Tissue Impairment or who had received bisphosphonates in the last three months were excluded; this meant that most patients had had a prior response longer than 24 months, which the usual time that bisphosphonates are given in the Spanish trials. 
Variables for evaluation
The main end-point was TNT, that was calculated as time that elapsed between the inclusion in the protocol, and the moment in which new antimyeloma therapy was initiated based on the appearance of a clinical relapse or death of any cause. The appearance of a SPR was not considered as a clinical relapse but it was qualified as a cause for initiating anti-myeloma when considering the TNT.
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RESULTS
Baseline characteristics and protocol compliance
From June 2010 to July 2012, 100 patients were recruited: 51 in the ZOL group and 49in the no ZOL. Baseline characteristics of the patients at the moment of inclusion are shown in 17%, del(p53) 8%, t(4;14) 4% and t(14;x) 4%. Hemoglobin, creatinine, calcium, and B2M were normal (as per protocol). β 2 microglobulin and C-Reactive Protein were also normal in all cases. ZOL and no ZOL groups were well balanced for prognostic features, prior response, and time from diagnosis to the inclusion in the trial (Table 1) .
Regarding protocol compliance, 44 patients completed the 12 visits for the interventional phase of the trial and four terminated before completion due to patient refusal (n=2) and development of other diseases (n=2). The remaining 54 patients stopped the trial due to progression before 12 months (n=52), toxicity (n=1, osteonecrosis of the jaw) and initiation of cytotoxic therapy due to SPR (n=1).
The distribution among groups is summarized in Figure 1 .
-Page 6 -With a median follow-up for surviving patients of 38 months, TNT since inclusion in the study was 10.9 months for the overall series of patients ( Figure 2A figure 2A ]. Time to a new SRE was not reached during the trial follow-up, with a projected percentage of SRE of 21.5% at four years and the overall survival from inclusion in the trial was 47 months ( Figure 2B ).
Efficacy
Myeloma responses were not observed during the treatment with ZOL, and therefore no antitumor effect of ZOL therapy was demonstrated. Of note, two patients in the control group experienced small M-component reductions that were not sustained over time. However, the proportion of patients progressing to symptomatic disease was lower in the ZOL group (n=34, 67%) as compared with the no ZOL group (n=41, 83%, P = 0.05), although this only partially translated into differences in the survival curves. Accordingly, TNT was slightly longer for the ZOL group (median of Concerning SRE, 16 events were reported in the trial: 5 vertebral fractures, 4 non-vertebral fractures, 2 cases of hypercalcemia, 3 skeletal cord compressions, and 2 cases of radiotherapy or bone surgery requirement, and they were related with an important number of total deaths (11/37).
Consequently, the actuarial 3-year OS for patients suffering a new SRE was 31% while it was 66% for patients free of new SREs (p=0.047). Interestingly, only 2 out of 14 SRE events appeared in the ZOL group. Consequently, the use of ZOL was associated with significantly less SREs than in the ZOL group. The projected 4-year risk of SRE was 6% for patients in the ZOL group vs. 40% in the No ZOL group (P< 0.001) ( Figure 3C ).
A trend for a longer OS was observed for the ZOL vs. No ZOL groups, with a 3-year projected OS of 73% vs. 46% ( Figure 3D ). Interestingly, the effects over OS were more evident in those patients who had more advanced bone disease. Thus, there were 68 patients with prior osteolytic lesions (32 treated and 36 not treated with ZOL) and the 3-year OS was longer for patients treated than for not treated with ZOL (61% vs. 32%, p=0.064). In addition, there were 36 patients who had had SREs before inclusion, and the 3-year OS was better for patients treated (n=18) than untreated (n=18) (69% vs. 20%, p=0.016).
Toxicity
All patients were evaluated for toxicity. Globally, 29 adverse events (AE) were registered in17 patients (8 for ZOL and 9 for no ZOL. Table 3 ): 12 grade 1, 9 grade 2 and 8 grade 3. There were no grade 4 AEs and there were no significant differences in the frequency of AE between the experimental and control arms (Table 3 ). Eight AEs in 6 patients (three in each group) were considered Severe Adverse Events (SAEs). All SAEs were considered related to underlying disease and resolved with appropriate therapy with the exception of the ONJ that was related to ZOL administration and caused trial discontinuation. There were two renal problems that presented in the control group and no patient developed any thromboembolic event during the trial.
DISCUSSION
Intravenous BP are the standard of care for the prevention of SRE and treatment of hypercalcemia in patients with MM. 4 In addition, some randomized trials have shown clinical benefits for BP in these patients when they are administered during cytotoxic therapy. [8] [9] [10] These results and some preclinical studies argue in favor of an antimyeloma effect for the most potent BP. The present randomized trial, do not support a direct antitumor effect for intravenous ZOL when administered as single therapy in myeloma patients at biochemical relapse since no reduction in M-component or prolongation in TNT was observed. However, upon considering that clinical progressions in the control group were mainly due to bone disease, we may counter-argue in favor of the use of ZOL in patients at biochemical relapse.
The hypothesis of an antitumor effect of BP has long been evaluated in MM 19, 20 and other tumors. 21 Since the initial observation that intravenous pamidronate could prolong the OS in some subsets of MM patients vs. placebo, 22 several groups have highlighted different direct and indirect mechanisms by which BP can exert and antitumor effect, especially in MM. [5] [6] [7] 23 This hypothesis has been partially confirmed in vivo in two different clinical trials, where the use of zoledronic acid resulted in a higher rate of response, 8 and a longer PFS and OS. Several studies have also evaluated the antitumor effect of BP monotherapy in patients with asymptomatic/smoldering MM. [11] [12] [13] [14] [15] [16] Although they demonstrated some benefit of BP on bone resorption, no clear tumor responses or benefit in terms of PFS or OS were observed. Probably, smoldering MM is not the ideal target population since due to their low rate of progression 24 it would require a large patient population and long follow up to demonstrate a survival benefit for a drug that, if it has any anti-tumor activity, it would be minor.
In our study, we decided to evaluate the potential antitumor efficacy of ZOL as a single agent with a similar approach, but targeting a different patient population (biochemical relapses) due to three reasons. First, biochemical relapses are very frequent. 25, 26 Second, most patients will require therapy very soon; Fernandez-Larrea et al have recently reported that most of these patients need therapy with a median time of 5.6 months after transplant, 27 which is concordant with the estimations done from the VISTA trial in non-transplant candidates patients upon comparing TTP and TNT. 28 Third, there is no universal consensus on how to treat these patients and many physicians prefer not treat until symptoms emerge. 29 As above mentioned, in the present study the use of ZOL as single therapy was not directly associated with an antitumor effect, since no reductions in the M-component were seen. However, fewer patients progressed in the ZOL group when compared to those in the abstention arm (67% vs.
87%, P = 0.05). This translated into a trend to longer, but not statistically significant, TCS and TNT (13.4 and 16 in the ZOL group as compared to 10.1 and 10 months in the control group, respectively).
Moreover, it is important to highlight that TNT was 10 months in the control group, longer than the expected 5-6 months. 27, 28 This can be explained because patients included in this trial were a selected low risk population, since they were patients in biochemical relapse who had had a previous long response (longer than 24 months, the time that Spanish protocols maintain the bisphosphonate therapy). This selection could partially explain why the differences between the treatment and abstention groups were not as high as predicted. An important observation was the significantly different pattern of symptomatic progression observed for patients in the experimental vs. control group, since in the latter group myeloma mainly progressed with bone disease, while ZOL patients mainly progressed with other symptoms, such as anemia. Such differential pattern could be related with the marginal benefits observed in OS for ZOL treated patients in the absence of clear improvements in TCS. A similar discrepancy was also observed in the MRC IX trial, where the OS was more pronouncedly increased with ZOL therapy than the PFS. 9 It is conceivable that the low incidence of SREs and other potential MM complications could be the basis this more pronounced benefit for ZOL therapy over the OS.
Development of SRE is an important complication of MM that results in high morbidity, mortality, and costs present report and in the literature. [30] [31] [32] [33] The use of ZOL resulted here in a very important reduction of SRE with respect to controls (4% vs. 33%), with a 4-year accumulated SRE of 6% vs. 40% (P< 0.001). This support several other reports in which the use of BP always translated into a reduction of SRE. 8, 9, [11] [12] [13] [14] [15] [16] 22 This reduction in the SREs could also help to explain why the OS was marginally favored by the use of ZOL, with a more pronounced effect in patients with bone disease or SRE, as the MRC trial already demonstrated. 9 However, the number of patients and differences in this study are limited, which should be considered for a correct interpretation. New image techniques could identify patients with no relevant bone disease and low benefit expectations from bisphosphonate therapy, but a global interpretation of our findings point out that use of ZOL has an evident clinical benefit for MM patients in the setting of asymptomatic biochemical relapses. Since ZOL therapy is not an expensive strategy an it is associated with very few AE, it can be considered as a change in the clinical standard of care of these patients in favor of a more active approach versus the current commonly used watch-and-wait strategy. Accordingly, we recommend the use of ZOL therapy in patients under biochemical relapses for at least 12 months; in case of symptomatic disease development, BP use should follow the rules of the rescue protocol, while in those patients who remain asymptomatic after 1 year of ZOL, therapy should be maintained following the current recommendations of the IMWG, that favor the use of BP therapy until progression for patients who are not in complete or very good partial response. 4 In summary, this randomized trial demonstrates that early single therapy with ZOL reduces the risk of progression with symptomatic bone disease and minimizes the incidence of SREs without significant toxicity in MM patients with asymptomatic relapse, and accordingly it should be considered as a new standard of care for this group of patients. 
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TABLES
Inclusion and exclusion criteria
Signed informed consent. Relapse was defined according to the IMWG criteria defined in 2006, 1 as a re-positivization of a previously negative immunofixation (two samples) or increase of ≥ 25% in the serum M-component (the absolute increase had to be 0.5 g/dl), or in the urine M-component (the absolute increase had to be ≥ 200 mg/24 h), or increase of ≥10 mg/dl in the difference between involved and uninvolved FLC levels (this criteria only applies to patients without measurable serum and urine M-protein levels), or increase in the bone marrow plasma cell percentage (the absolute percentage had to be ≥10%). Patients treated with any symptom of myeloma Related Organ or Tissue Impairment or who had received bisphosphonates in the last three months were excluded; this meant that most patients had had a prior response longer than 24 months, which the usual time that bisphosphonates are given in the Spanish trials. 
Variables for evaluation
The main end-point was TNT, that was calculated as time that elapsed between the inclusion in the protocol, and the moment in which new antimyeloma therapy was initiated based on the appearance of a clinical relapse (end organ damage) (point 2 of the exclusion criteria), or death of any cause. The appearance of a SPR was not considered as a clinical relapse but it was qualified as a cause for initiating anti-myeloma when considering the TNT. The only exception to consider therapy and an event for TNT required a doubling of the M-component in 2 consecutive measurements separated by less than or equal to 2 months; or an increase in the absolute levels of serum M protein by more than or equal to 1 g/dL, or urine M protein by more than or equal to 500 mg/24 hours, or involved FLC level by more than or equal to 20 mg/dL (plus an abnormal FLC ratio) in 2 consecutive measurements separated by less than or equal to 2 months. Collected data were exported to SPSS v15 (SPSS Inc, Armonk, New York) for further statistical analysis. T-test and Chisquare-test were used to identify statistically significant differences between groups. TNT, TNS, and overall survival (OS) distribution curves were plotted using the Kaplan-Meier method, using the log-rank test for comparisons. The effects of multiple parameters on survival were evaluated in all patients using a two-sided log-rank test.
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